Literature DB >> 1336346

Mode of antiviral action of penciclovir in MRC-5 cells infected with herpes simplex virus type 1 (HSV-1), HSV-2, and varicella-zoster virus.

D L Earnshaw1, T H Bacon, S J Darlison, K Edmonds, R M Perkins, R A Vere Hodge.   

Abstract

The metabolism and mode of action of penciclovir [9-(4-hydroxy-3-hydroxymethylbut-1-yl)guanine; BRL 39123] were studied and compared with those of acyclovir. In uninfected MRC-5 cells, low concentrations of the triphosphates of penciclovir and acyclovir were occasionally just detectable, the limit of detection being about 1 pmol/10(6) cells. In contrast, in cells infected with either herpes simplex virus type 2 (HSV-2) or varicella-zoster virus (VZV), penciclovir was phosphorylated quickly to give high concentrations of the triphosphate ester. Following the removal of penciclovir from the culture medium, penciclovir-triphosphate remained trapped within the cells for a long time (half-lives, 20 and 7 h in HSV-2- and VZV-infected cells, respectively). In HSV-2-infected cells, acyclovir was phosphorylated to a lesser extent and the half-life of the triphosphate ester was only 1 h. We were unable to detect any phosphates of acyclovir in VZV-infected cells. (S)-Penciclovir-triphosphate inhibited HSV-1 and HSV-2 DNA polymerase competitively with dGTP, the Ki values being 8.5 and 5.8 microM, respectively, whereas for acyclovir-triphosphate, the Ki value was 0.07 microM for the two enzymes. Both compounds had relatively low levels of activity against the cellular DNA polymerase alpha, with Ki values of 175 and 3.8 microM, respectively. (S)-Penciclovir-triphosphate did inhibit DNA synthesis by HSV-2 DNA polymerase with a defined template-primer, although it was not an obligate chain terminator like acyclovir-triphosphate. These results provide a biochemical rationale for the highly selective and effective inhibition of HSV-2 and VZV DNA synthesis by penciclovir and for the greater activity of penciclovir than that of acyclovir when HSV-2-infected cells were treated for a short time.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1336346      PMCID: PMC245539          DOI: 10.1128/AAC.36.12.2747

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  19 in total

1.  The herpes simplex virus type 1 UL42 gene product: a subunit of DNA polymerase that functions to increase processivity.

Authors:  J Gottlieb; A I Marcy; D M Coen; M D Challberg
Journal:  J Virol       Date:  1990-12       Impact factor: 5.103

2.  Nonstructural proteins of herpes simplex virus. I. Purification of the induced DNA polymerase.

Authors:  K L Powell; D J Purifoy
Journal:  J Virol       Date:  1977-11       Impact factor: 5.103

3.  High-performance liquid chromatographic method for the determination of 9-(4-hydroxy-3-hydroxymethylbut-1-yl)guanine (BRL-39123) in human plasma and urine.

Authors:  S E Fowles; D M Pierce
Journal:  Analyst       Date:  1989-11       Impact factor: 4.616

4.  Mechanism of inhibition of adenovirus DNA replication by the acyclic nucleoside triphosphate analogue (S)-HPMPApp: influence of the adenovirus DNA binding protein.

Authors:  Y M Mul; R T van Miltenburg; E De Clercq; P C van der Vliet
Journal:  Nucleic Acids Res       Date:  1989-11-25       Impact factor: 16.971

5.  Selection of an oral prodrug (BRL 42810; famciclovir) for the antiherpesvirus agent BRL 39123 [9-(4-hydroxy-3-hydroxymethylbut-l-yl)guanine; penciclovir].

Authors:  R A Vere Hodge; D Sutton; M R Boyd; M R Harnden; R L Jarvest
Journal:  Antimicrob Agents Chemother       Date:  1989-10       Impact factor: 5.191

6.  Herpes simplex virus type 1 DNA polymerase. Mechanism of inhibition by acyclovir triphosphate.

Authors:  J E Reardon; T Spector
Journal:  J Biol Chem       Date:  1989-05-05       Impact factor: 5.157

7.  Mechanism of selective inhibition of varicella zoster virus replication by 1-beta-D-arabinofuranosyl-E-5-(2-bromovinyl)uracil.

Authors:  T Yokota; K Konno; S Mori; S Shigeta; M Kumagai; Y Watanabe; H Machida
Journal:  Mol Pharmacol       Date:  1989-08       Impact factor: 4.436

8.  Mode of action of 9-(4-hydroxy-3-hydroxymethylbut-1-yl)guanine (BRL 39123) against herpes simplex virus in MRC-5 cells.

Authors:  R A Hodge; R M Perkins
Journal:  Antimicrob Agents Chemother       Date:  1989-02       Impact factor: 5.191

9.  Herpes simplex virus type 1 and human DNA polymerase interactions with 2'-deoxyguanosine 5'-triphosphate analogues. Kinetics of incorporation into DNA and induction of inhibition.

Authors:  J E Reardon
Journal:  J Biol Chem       Date:  1989-11-15       Impact factor: 5.157

10.  Nucleic acid hybridization, a method to determine effects of antiviral compounds on herpes simplex virus type 1 DNA synthesis.

Authors:  H Gadler; A Larsson; E Sølver
Journal:  Antiviral Res       Date:  1984-04       Impact factor: 5.970

View more
  50 in total

1.  Selection and characterization of varicella-zoster virus variants resistant to (R)-9-[4-hydroxy-2-(hydroxymethy)butyl]guanine.

Authors:  T I Ng; Y Shi; H J Huffaker; W Kati; Y Liu; C M Chen; Z Lin; C Maring; W E Kohlbrenner; A Molla
Journal:  Antimicrob Agents Chemother       Date:  2001-06       Impact factor: 5.191

Review 2.  Positron emission tomography (PET): expanding the horizons of oncology drug development.

Authors:  Lisa A Hammond; Louis Denis; Umber Salman; Paul Jerabek; Charles R Thomas; John G Kuhn
Journal:  Invest New Drugs       Date:  2003-08       Impact factor: 3.850

3.  Therapeutic Options for Herpes Simplex Infections.

Authors:  Eugene Au; Stephen L. Sacks
Journal:  Curr Infect Dis Rep       Date:  2003-02       Impact factor: 3.725

4.  Penciclovir is a selective inhibitor of hepatitis B virus replication in cultured human hepatoblastoma cells.

Authors:  B E Korba; M R Boyd
Journal:  Antimicrob Agents Chemother       Date:  1996-05       Impact factor: 5.191

Review 5.  Current recommendations for the treatment of genital herpes.

Authors:  D T Leung; S L Sacks
Journal:  Drugs       Date:  2000-12       Impact factor: 9.546

Review 6.  Laser treatment of recurrent herpes labialis: a literature review.

Authors:  Carlos de Paula Eduardo; Ana Cecilia Corrêa Aranha; Alyne Simões; Marina Stella Bello-Silva; Karen Muller Ramalho; Marcella Esteves-Oliveira; Patrícia Moreira de Freitas; Juliana Marotti; Jan Tunér
Journal:  Lasers Med Sci       Date:  2013-04-13       Impact factor: 3.161

7. 

Authors:  A Amor; M Sánchez-Conde
Journal:  Medicine (Madr)       Date:  2009-01-06

8.  In vitro antiviral activity of penciclovir, a novel purine nucleoside, against duck hepatitis B virus.

Authors:  T Shaw; P Amor; G Civitico; M Boyd; S Locarnini
Journal:  Antimicrob Agents Chemother       Date:  1994-04       Impact factor: 5.191

9.  Comparative activity of selected antiviral compounds against clinical isolates of varicella-zoster virus.

Authors:  G Andrei; R Snoeck; D Reymen; C Liesnard; P Goubau; J Desmyter; E De Clercq
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1995-04       Impact factor: 3.267

Review 10.  The clinical pharmacokinetics of famciclovir.

Authors:  K S Gill; M J Wood
Journal:  Clin Pharmacokinet       Date:  1996-07       Impact factor: 6.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.